Total synthesis and biological evaluation of structural analogs of compactin and dihydromevinolin
- 1 October 1987
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 30 (10) , 1858-1873
- https://doi.org/10.1021/jm00393a030
Abstract
The full experimental details for the total synthesis of (+)-compactin and 19 structural analogues are reported. We have evaluated three classes of analogues as inhibitors of 3-hydroxy-3-methlglutaryl-coenzyme A reductase: (1) functional and stereoisomeric analogues that possess the full carbon skeleton of compactin or dihydromevinolin, (2) functional analogues in which one carbon of the skeleton has been replaced by oxygen, and (3) analogues in which all of the 3,5-dihydroxyvaleric acid moiety has been omitted. Our most potent inhibitors belong to the first class of analogues. Compounds 42 (5-ketocompactin) and 69 (5-ketodihydromevinolin) are as active as the natural products compactin and dihydromevinolin, respectively (I50 = 1-20 nM). The corresponding enones 37 and 68 are less active, having I50 values 20-30 times larger. Inverting the stereochemistry at C-3 or C-5 or about the hexahydronaphthalene ring of compactin results in the elevation of the I50 to values in the micromolar range, comparable to the KM of the natural substrate 3-hydroxy-3-methylglutaryl coenzyme A. Class 2 analogues are active in this concentration range also. The synthetic sequence developed for compactin and its analogues includes a new method that permits the selective preparation of either the R or the S epimer at C-3 of the 3,5-dihydroxyvaleric acid moiety. This entails the reaction of anhydride 9 with either (R)- or (S)-1-phenylethanol in the presence of 4-(N,N-dimethylamino)pyridine and triethylamine. The prochiral recognition is surprisingly high; under optimum conditions, the reaction of 9 with (R)-1-phenylethanol leads to a 15:1 ratio of diesters 17 and 18.This publication has 18 references indexed in Scilit:
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.Proceedings of the National Academy of Sciences, 1980
- The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme—A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicksAtherosclerosis, 1980
- Therapeutic effects of ML-236B in primary hypercholesterolemiaAtherosclerosis, 1980
- Kinetic Analysis of the Reaction Catalyzed by Rat‐Liver 3‐Hydroxy‐3‐methylglutaryl‐coenzyme‐A Reductase Using Two Specific InhibitorsEuropean Journal of Biochemistry, 1979
- Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase.Journal of Lipid Research, 1979
- Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A ReductaseEuropean Journal of Biochemistry, 1977
- Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactumJournal of the Chemical Society, Perkin Transactions 1, 1976